RSV Vaccine Protects Seniors, Boosts Public Health
- Okay, here's a breakdown of the provided text, focusing on key information about RSV in older adults. I'll organize it into sections for clarity.
- * RSV significantly impacts older adults (60+), even those with prior exposure.
- * Mild Symptoms: Congested/runny nose, dry cough, low-grade fever, sore throat, sneezing, headache (resemble a common cold).
Okay, here’s a breakdown of the provided text, focusing on key information about RSV in older adults. I’ll organize it into sections for clarity.
1. Overview of RSV in Older Adults
* RSV significantly impacts older adults (60+), even those with prior exposure.
* It can lead to severe infection,hospitalization,and complications.
* An estimated 110,000-180,000 adults 50+ are hospitalized with RSV annually in the US.
2. Symptoms of RSV
* Mild Symptoms: Congested/runny nose, dry cough, low-grade fever, sore throat, sneezing, headache (resemble a common cold).
* Severe Symptoms: Fever, severe cough, wheezing, rapid/tough breathing, bluish skin color.
* RSV can worsen existing conditions like asthma, COPD, or heart failure, possibly leading to hospitalization or death.
3. Vaccination Recommendations (as of the text’s writing)
* The CDC recommends a single dose of any of the 3 FDA-approved RSV vaccines for:
* All adults 75 years and older.
* Adults 60-74 years old who are at increased risk of severe illness.
* Vaccines:
* Arexvy (GSK) – first approved in May 2023.
* Abrysvo (Pfizer) – Approved in May 2023.
* mRESVIA (Moderna) – Approved in May 2024.
* Indications for these vaccines have been updated as their initial approval.
4. Why Older adults Remain Vulnerable (despite Prior Exposure)
* Natural infection doesn’t provide sufficient long-term protection against severe RSV disease.
* This highlights the importance of vaccination.
5. Factors Increasing Risk in older Adults (as examined in a review)
* Structural Lung Decline: Loss of lung elasticity, chest wall stiffening, reduced respiratory reserve.
* Impaired Defenses: Reduced mucociliary clearance, weakened cough, diminished airway surface liquid. These allow RSV to penetrate deeper into the airways.
* Comorbidities: Chronic conditions increase risk.
* Immunosenescence: Age-related decline in immune function.
* Impaired Antibody Responses: Reduced ability to mount an effective immune response.
Critically important Note: Medical information changes rapidly. This summary is based solely on the provided text. For the most up-to-date recommendations and information, consult with a healthcare professional or refer to official sources like the CDC and FDA.